Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ibd/izz117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infliximab-Induced Interstitial Pneumonitis: A Case Report.
Cureus
June 2023
Pulmonology, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, SAU.
Anti-tumor necrosis factor inhibitors are increasingly being recommended to treat and control a wide range of diseases, including Crohn's disease, ulcerative colitis, rheumatoid, and psoriatic arthritis. Serious pulmonary consequences, ranging from infectious disease to pulmonary edema, airway involvement, and even interstitial lung disease, are well-known multisystemic side effects. Interstitial lung disease is a well-known but uncommon condition.
View Article and Find Full Text PDFInfliximab-Induced Non-specific Interstitial Pneumonitis in a Patient With Ulcerative Colitis (UC).
Cureus
December 2022
Pulmonary and Critical Care Medicine, Norwalk Hospital, Norwalk, USA.
Infliximab belongs to the family of tumor necrosis factor (TNF) alpha inhibitors and since its development, it has revolutionized treatment for both rheumatological diseases and inflammatory bowel disease (IBD). In IBD specifically, it has shown to result in symptomatic, endoscopic, and histological remission which is why it is one of the most widely used treatments for moderate to severe IBD. While common side effects include infections due to immunosuppression, cytopenias and hepatotoxicity, interstitial lung disease (ILD) has been infrequently reported to result from inflixiamb use.
View Article and Find Full Text PDFInfliximab-induced interstitial lung disease.
BMJ Case Rep
October 2021
Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
A 70-year-old man was referred to our respiratory department with non-productive cough over the past 6 months. High-resolution CT revealed reticular pattern with basal and peripheral predominance, centrilobular nodules and mild ground glass opacities. Serology tests were normal and bronchoalveolar lavage revealed lymphocytosis.
View Article and Find Full Text PDFCase report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn's disease patient upon infliximab-induced lupus-like syndrome.
Therap Adv Gastroenterol
September 2021
Department of Medicine 1, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany.
Anti-tumor necrosis factor (TNF) antibodies have become an indispensable part in the therapeutic landscape of treating inflammatory bowel disease (IBD) patients. Nevertheless, they can be associated with the occurrence of severe systemic side effects. Here, we report the case of a 23-year-old patient with ileocolonic Crohn's disease in endoscopic remission under ongoing anti-TNF infliximab therapy with occurrence of novel generalized arthralgia, pleuritic chest pain, and dyspnea.
View Article and Find Full Text PDFInfliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
J Hepatol
January 2022
Landspitali - The National University Hospital of Iceland, Section of Gastroenterology and Hepatology, Reykjavik, Iceland; University of Iceland, Faculty of Medicine, Reykjavik, Iceland.
Article Synopsis
- Infliximab can cause drug-induced liver injury (DILI), specifically autoimmune hepatitis, and the effectiveness of corticosteroids for treatment is not well established.
- A study identified 36 patients treated with infliximab who developed elevated liver tests, finding that nearly half received corticosteroids, which were associated with a slower peak liver enzyme increase.
- The corticosteroid group showed good treatment responses with a significant resolution of liver test abnormalities over time, and no relapses occurred during follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!